04 Nephroprotective therapies: which one and when to start? (SGLT2i, GLP-1, MRA)

Explain that the management of LN entails two equally important pillars: immunosuppressive treatment and nephroprotective measures 03

Authors

Institutions

Publication Details

Journal
Abstracts
Published
2025-10-01
DOI
https://doi.org/10.1136/lupus-2025-la.4
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

04 Nephroprotective therapies: which one and when to start? (SGLT2i, GLP-1, MRA)

Eva Schrezenmeier
Abstracts
Diabetes Treatment and Management
article

04 Nephroprotective therapies: which one and when to start? (SGLT2i, GLP-1, MRA)

Eva Schrezenmeier
article en

Abstract

Explain that the management of LN entails two equally important pillars: immunosuppressive treatment and nephroprotective measures 03

Abstracts
Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 62%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

04 Nephroprotective therapies: which one and when to start? (SGLT2i, GLP-1, MRA) — Eva Schrezenmeier · Abstracts (2025) | TGRS Research Map | TGRS